Guardion Health Sciences Azioni (OTC: GHSI)

Ultime notizie per Guardion Health Sciences (OTC:GHSI) Azioni

Guardion Health Sciences

Guardion Health Sciences Inc clinical nutrition company that develops and distributes clinically supported dietary supplements and medical foods. It offers a portfolio of science-based, clinically supported products designed to support consumers, healthcare professionals and providers, and their patients by supporting bone health, eye health, cardiovascular health, and brain health through nutrients such as Calcium, Vitamin D, Vitamin K, Carotenoids, and Omega-3s.

Guardion Health Sciences Inc

Banzai International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) reported quarterly losses of $(2.68) per share. This is a 712.12 percent decrease over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $1.08 million which missed the analyst consensus estimate of $1.20 million by 9.95 percent. This is a 2.51 percent decrease over sales of $1.11 million the same period last year.

Earnings

Earnings Misses

News

BNZI

Banzai International Q3 EPS $(2.68) Down From $(0.33) YoY, Sales $1.08M Miss $1.20M Estimate

FBYD

Falcons Beyond Global Q3 EPS $0.46, Sales $2.07M Up From $1.58M YoY

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) with a Buy and maintains $7 price target.

Price Target

Analyst Ratings

TSHA

Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $7 Price Target

Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) reported quarterly earnings of $0.02 per share. This is a 100.14 percent increase over losses of $(14.15) per share from the same period last year. The company reported $132.00 thousand in sales this quarter. This is a 221.95 percent increase over sales of $41.00 thousand the same period last year.

ADGM

Adagio Medical Holdings Q3 EPS $0.02 Up From $(14.15) YoY, Sales $132.00K Up From $41.00K YoY

Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) with a Buy and maintains $55 price target.

CRVO

Chardan Capital Maintains Buy on CervoMed, Maintains $55 Price Target

The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.

HALO

Evotec Confirms Receipt Of Non-binding Expression Of Interest From Halozyme Therapeutics With An Offer Price Of EUR 11.00 Per Share

PEDEVCO (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PED#AMEX">PED</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.01 by 200 percent. The company reported quarterly sales of $9.100 million which beat the analyst consensus estimate of $8.859 million by 2.72 percent. This is a 24.15 percent increase over sales of $7.330 million the same period last year.

Earnings Beats

PEDEVCO Q3 2024 GAAP EPS $0.03 Beats $0.01 Estimate, Sales $9.100M Beat $8.859M Estimate

Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) reported quarterly losses of $(4.54) per share which beat the analyst consensus estimate of $(7.12) by 36.24 percent. This is a 30.9 percent increase over losses of $(6.57) per share from the same period last year.

FBRX

Forte Biosciences Q3 EPS $(4.54) Beats $(7.12) Estimate

Jefferies analyst Omar Nokta maintains Safe Bulkers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SB#NYSE">SB</a>) with a Buy and maintains $6 price target.

Jefferies Maintains Buy on Safe Bulkers, Maintains $6 Price Target

Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 47.92 percent increase over losses of $(0.48) per share from the same period last year.

RVPH

Reviva Pharmaceuticals Q3 2024 GAAP EPS $(0.25) Beats $(0.26) Estimate

Nova Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVFY#NASDAQ">NVFY</a>) reported quarterly losses of $(0.72) per share. This is a 13.25 percent increase over losses of $(0.83) per share from the same period last year. The company reported $2.62 million in sales this quarter. This is a 5.65 percent increase over sales of $2.48 million the same period last year.

NVFY

Nova Lifestyle Q3 EPS $(0.72) Up From $(0.83) YoY, Sales $2.62M Up From $2.48M YoY

Hedge Funds

General

FLUT

SPOT

ValueAct Holdings' Q3 2024 13F Filing Reveals Full Exits From Spotify, Fiserv, KKR & Co., New York Times With 1.34M Shares, And Flutter Entertainment

COLL

COLLEGIUM PHARMACEUTICAL Announced That Health Canada Has Approved Its Drug Jornay-PM For The Treatment Of ADHD In Children

Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are trading higher in Thursday&#8217;s after-hours session after the company announced it will transfer its stock listing <a href="https://www.benzinga.com/pressreleases/24/11/b41988795/palantir-announces-transfer-of-stock-exchange-listing-to-nasdaq">to the Nasdaq</a>.
What Happened: After the market close on Thursday, Palantir announced that it would transfer the listing of its Class A common stock from the New York Stock Exchange to the Nasdaq Global Select Market.
Palantir said it expects to begin trading as a Nasdaq-listed company on Nov. 26. The stock will continue to trade under the ticker symbol &#8220;PLTR.&#8221;
&#8220;Upon transferring, Palantir anticipates meeting the eligibility requirements of the Nasdaq-100 Index,&#8221; the company said.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41984278/jim-simons-renaissance-technologies-shifts-gears-microsoft-in-tesla-out-palantir-on-top">Jim Simons&#8217; Renaissance Technologies Shifts Gears: Microsoft In, Tesla Out, Palantir On Top</a>
Palantir has been one of the hottest stocks of the year, having gained approximately 245% year-to-date, driven by the company&#8217;s positioning in the <a href="http://benzinga.com/topic/ai">AI</a> space. 
Palantir shares really took off at the beginning of November after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">strong quarterly results</a> driven by&nbsp;"unrelenting" AI demand. 
Revenue jumped 30% year-over-year on continued strength in the U.S. customer count grew 39% year-over-year after the company closed 104 deals worth over $1 million during the quarter.
"The growth of our business is accelerating, and our financial performance is exceeding expectations as we meet an unwavering demand for the most advanced artificial intelligence technologies from our U.S. government and commercial customers,&#8221;&nbsp;Alex Karp, co-founder and CEO of Palantir, said in a letter to shareholders.
PLTR Price Action: Palantir shares were up 3.87% in after-hours, trading at $61.47 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

After-Hours Center

Movers

Tech

PLTR

Palantir Stock Is Rising After The Bell: What's Going On?

Trading Ideas

GOOG

GOOGL

Pershing Square Capital's Q3 2024 13F Filing Reveals Reduced Stakes In Hilton Worldwide By 18% To 7.37M Shares, Chipotle Mexican Grill By 8%, Restaurant Brands Intl By 1% To 23.0M Shares, And Alphabet Class C And Class A By 9%

Pershing Square Capital's Q3 2024 13F Filing Shows New Stakes In Brookfield Corp With 25.88M Shares, Nike With 13.24M Shares, And Seaport Entertainment Group With 2.09M Shares Each In Common Stock And Rights

RBLX

ValueAct Holdings' Q3 2024 13F Filing Indicates Increased Stakes In Walt Disney By 22% To 7.46M Shares And Roblox By 341% To 10.14M Shares

LLYVA

LLYVK

ValueAct Holdings' Q3 2024 13F Filing Shows New Stakes In Meta Platforms With 211.5K Shares, Live Nation Entertainment With 1.01M Shares, Visa With 373.6K Shares, Liberty Media Corp Series C With 1.34M Shares, And Liberty Media Corp Series A With 671.8K Shares

The loss is primarily attributable to a non-cash change in fair value of warrant liabilities related to common share price and warrant price appreciation during the quarter, production restart related operating expenses, and interest expense.

Sable Offshore Reports Q3 Net Income Of $(255.6)M

Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.39) by 33.33 percent. The company reported quarterly sales of $1.926 million which beat the analyst consensus estimate of $1.000 million by 92.60 percent. This is a 647.65 percent increase over sales of $257.606 thousand the same period last year.

MRKR

Marker Therapeutics Q3 2024 GAAP EPS $(0.26) Beats $(0.39) Estimate, Sales $1.926M Beat $1.000M Estimate

Guardion Health Sciences reports Q1 results

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Guardion Health Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ghsi-stock-quote/">GHSI</a>) just reported results for the first quarter of 2024.<ul><li>Guardion Health Sciences reported earnings per share of -$3.71. This was below the analyst estimate for EPS of -88 cents.</li><li>The company reported revenue of $3.00 million.</li><li>This was 3.86% worse than the analyst estimate for revenue of $3.12 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ghsi-stock-earnings-guardion-health-sciences-for-q1-of-2024/">GHSI Stock Earnings: Guardion Health Sciences Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GHSI Stock Earnings: Guardion Health Sciences Misses EPS, Misses Revenue for Q1 2024

Tandem Diabetes Care, Guardion Health, GT Biopharma among healthcare movers

Guardion Health Sciences (GHSI) has issued an announcement. Guardion Health Sciences, Inc. has mutually agreed with Craig Sheehan, its Chief Commer...

Guardion Health Sciences CCO Sheehan Exits with Compensation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Guardion Health Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ghsi-stock-quote/">GHSI</a>) just reported results for the second quarter of 2024.<ul><li>Guardion Health Sciences reported earnings per share of -$1.64. This was below the analyst estimate for EPS of -66 cents.</li><li>The company reported revenue of $72,918.</li><li>This was 97.73% worse than the analyst estimate for revenue of $3.21 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ghsi-stock-earnings-guardion-health-sciences-for-q2-of-2024/">GHSI Stock Earnings: Guardion Health Sciences Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GHSI Stock Earnings: Guardion Health Sciences Misses EPS, Misses Revenue for Q2 2024

Guardion Health Sciences reports Q2 results

Guardion Health Sciences declares $5.00 dividend

Guardion Health Sciences ( ($GHSI) ) has shared an announcement. Guardion Health Sciences, Inc. has announced the departure of its President and CE...

Guardion Health Sciences CEO Jan Hall Set to Depart

Guardion Health Sciences announces adoption of plan of dissolution and liquidation

Guardion Health Sciences ( ($GHSI) ) has issued an announcement. Guardion Health Sciences, Inc. has initiated a significant corporate shakeup, anno...

Guardion Health Sciences Announces Delisting and New Interim CEO

AONC

BDRX

GHSI

GTBP

LSDI

MYMD

SABS

TNDM

XYLO

Small Cap

Opinion

Press Releases

Thinking about buying stock in Guardion Health Sciences, Minim, Revelation Biosciences, Nyxoah, or Pixelworks?

Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023

Guardion Health Sciences Announces

Guardion Health Sciences Announces its Largest Stockholder Has Voted in Favor of Proposals to Sell the Viactiv Business and the Liquidation Plan at the Company's Special Meeting of Stockholders to be held on May 23, 2024

Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business

Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor's Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution

Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024

Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock

Guardion Health Sciences Announces Adoption of Plan of Dissolution and Liquidation; Appointment of Interim President and CEO

Comments

Guardion Health Sciences

Notizie

Ultime notizie per Guardion Health Sciences (OTC:GHSI) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO